Natixis Advisors
ALNY icon

Natixis Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Natixis Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.7M Sell
75,311
-2,705
-3% -$816K 0.03% 508
2026
Q1 		$25.8M Buy
78,016
+33,681
+76% +$11.5M 0.04% 421
2025
Q4 		$17.6M Buy
44,335
+22,653
+104% +$10M 0.03% 523
2025
Q3 		$9.89M Buy
21,682
+11,573
+114% +$4.71M 0.01% 662
2025
Q2 		$3.3M Buy
+10,109
New +$2.8M 0.01% 938
2025
Q1 		– Sell
-10,453
Closed -$2.46M – 1603
2024
Q4 		$2.46M Buy
10,453
+451
+5% +$119K ﹤0.01% 1030
2024
Q3 		$2.75M Buy
+10,002
New +$2.6M 0.01% 987
2022
Q2 		– Sell
-10,359
Closed -$1.69M – 1455
2022
Q1 		$1.69M Sell
10,359
-2,164
-17% -$330K 0.01% 1004
2021
Q4 		$2.12M Sell
12,523
-7,329
-37% -$1.36M 0.01% 927
2021
Q3 		$3.75M Buy
19,852
+8,461
+74% +$1.59M 0.02% 735
2021
Q2 		$1.93M Buy
+11,391
New +$1.67M 0.01% 920

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis Advisors's ALNY Position: Q2 2026 in Review

Natixis Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 3.5% in Q2 2026, selling an estimated $816K and leaving 75,311 shares worth $22.7M. The position accounts for 0.03% of the portfolio, ranked #508.

Natixis Advisors first reported a position in ALNY in Q2 2021 and has held it in 11 quarters since. The position peaked at $25.8M in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Natixis Advisors held 75,311 shares of Alnylam Pharmaceuticals worth $22.7M as of Q2 2026.
  • Natixis Advisors sold 2,705 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $816K.
  • Alnylam Pharmaceuticals made up 0.03% of Natixis Advisors's portfolio in Q2 2026, its #508 holding.
  • Natixis Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
  • Natixis Advisors's Alnylam Pharmaceuticals position peaked at $25.8M in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.